Cutaneous manifestations in inflammatory bowel disease (Review)

Ungureanu, Loredana; Cosgarea, Raluca; Badea, Mihail Alexandru; Vasilovici, Alina; Cosgarea, Ioana; Şenilă, Simona Corina

doi:10.3892/etm.2019.8321

Cited by 15 publications

(20 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PAN coded with ICD-9-CM 446.0 is not limited to cutaneous PAN. Rarely reported skin diseases in IBD (lichen planus, linear IgA bullous dermatosis, or epidermolysis bullosa acquisita) were not included [ 13 ]. Fifth, the severity of IBD cannot be ascertained from NHIRD, and thus the patients with early and subtle symptoms of IBD, not eligible for a catastrophic illness certificate (CIC), were not analyzed.…”

Section: Discussionmentioning

confidence: 99%

“…IBD patients with skin manifestations may present with higher disease activity, complications, and comorbidities [ 6 ]. Furthermore, EN and aphthous stomatitis parallel underlying intestinal disease activity, suggesting the importance of skin manifestations in IBD [ 5 , 13 , 14 , 15 ]. This evidence shows the importance of being aware that the skin manifestations in IBD may be an indication of disease activity and could decrease the diagnostic delay of other EIMs or IBD.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Temporal Relationships and Associations between Cutaneous Manifestations and Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study

Hung

Kuo

et al. 2021

JCM

View full text Add to dashboard Cite

The temporal relationships between inflammatory bowel disease (IBD)-associated cutaneous manifestations and IBD remain uncertain, with existing evidence mostly from separate cross-sectional studies. We sought to determine the risks of IBD-related dermatologic diseases before and after the diagnosis of IBD. We identified 2847 cases of IBD and 14,235 matched controls from the Taiwan National Health Insurance Research Database between 2003 and 2014. The risks of cutaneous manifestations before and after the diagnosis of IBD were estimated with multivariable-adjusted analyses. At diagnosis, IBD was associated with atopic dermatitis (odds ratio (OR) = 1.61; 95% confidence interval (CI), 1.14–2.28), erythema nodosum (OR = 7.44; 95%CI, 3.75–14.77), aphthous stomatitis (OR = 2.01; 95%CI, 1.72–2.35), polyarteritis nodosa (OR = 5.67; 95%CI, 2.69–11.98), rosacea (OR = 1.67, 95%CI = 1.19–2.35), and cutaneous T cell lymphoma (OR = 21.27; 95%CI, 2.37–191.00). IBD was associated with the subsequent development of pyoderma gangrenosum (hazard ratio (HR) = 17.79; 95%CI, 6.35–49.86), erythema nodosum (HR = 6.54; 95%CI, 2.83–15.13), polyarteritis nodosa (HR = 2.69; 95%CI, 1.05–6.90), hidradenitis suppurativa (HR = 2.48; 95%CI, 1.03–5.97), psoriasis (HR = 2.19; 95%CI, 1.27–3.79), rosacea (HR = 1.92; 95%CI, 1.39–2.65), and aphthous stomatitis (HR = 1.45; 95%CI, 1.22–1.72). This study clarified the associations and temporal relationships between cutaneous manifestations and IBD, highlighting the need for interdisciplinary care in the patient with specific dermatologic diseases presenting with abdominal symptoms, or the IBD patients with cutaneous lesions.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The Temporal Relationships and Associations between Cutaneous Manifestations and Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study

Hung

Kuo

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…Perianal lesions are observed in 36% of patients [ 4 , 11 ]. It may present as erythema, fissure, perianal stenosis, fecal incontinence, abscess, and fistulae (these two being more frequent); such lesions may also be observed in a peristomal region and abdominal scars due to laparotomy or umbilical ones creating enterocutaneous fistulae [ 4 , 8 ].…”

Section: Reviewmentioning

confidence: 99%

Mucocutaneous Manifestations of Inflammatory Bowel Disease

Álvarez-Payares¹,

Ramírez-Urrea²,

Correa-Parra³

et al. 2021

Cureus

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a chronic and incurable disease, of unknown etiology, associated with an unregulated immune response to environmental triggers in a genetically predisposed host. IBD affects mainly the gastrointestinal (GI) tract and includes Crohn's disease (CD) and ulcerative colitis (UC). However, a large percentage of patients may present with extraintestinal manifestations, including mucocutaneous ones (which are the most common) and dermatologic findings, such as erythema nodosum, pyoderma gangrenosum, and aphthous stomatitis (which are the most frequently occurring). According to pathophysiologic mechanisms, mucocutaneous manifestations of IBD are classified into five categories, namely, specific manifestations, associated manifestations, reactive manifestations, adverse effects of IBD therapy, and malabsorption manifestations. Recognizing such manifestations should not be performed only by a dermatologist but also other specialties such as internal medicine, gastroenterology, among others. This is because these manifestations can present before the IBD diagnosis, even in the absence of GI symptoms. Therefore, these skin lesions could be a fundamental tool for the earlier diagnosis of IBD. This review provides a comprehensive overview of the most common cutaneous manifestations of IBD with a focus on their epidemiology, diagnostic criteria, clinical presentation, and available medical treatment.

show abstract

“…При появлении таких осложнений рекомендуется консультация дерматолога, в большинстве случаев возможен контроль данных явлений с помощью местного лечения, а терапия анти-ФНО-α может быть продолжена (уровень доказательности 3) [6]. Вместе с тем, поскольку этот тип поражений кожи класс-специфичен для препаратов анти-ФНО-α, переключение на другой вид моноклональных антител к ФНО-α нецелесообразно, и рекомендуется замена генно-инженерной терапии на препарат другого класса: устекинумаб или ведолизумаб [20]. При сочетании БК с поражением суставов и псориазом кожи, псориатическим артритом или при псориазоподобных эффектах препаратов анти-ФНО-α препаратом выбора признан устекинумаб (моноклональные антитела к интерлейкинам 12/23).…”

Section: обсуждение клинического наблюденияunclassified

Joint lesions in inflammatory bowel diseases: the analysis of the Moscow regional patient registry and a clinical case

Таратина

Belousova

2020

Alʹm. klin. med.

View full text Add to dashboard Cite

Rationale: Extraintestinal manifestations (EIM) of an inflammatory bowel disease (IBD) are a sign of its more severe course. Joint lesions are most common among IBD EIM.Aim: To evaluate the prevalence and types of joint lesions in the population of IBD patients of the Moscow region.Materials and methods: We performed a retrospective analysis of medical files of the patients who were admitted to the Moscow Region Inflammatory Bowel Disease Center (MONIKI) for examination and treatment from August 1, 2019, to March 1, 2020. The study included 70 patients with confirmed diagnoses of IBD and confirmed or suspected involvement of the joints.Results: Thirty six of 70 patients with IBD and EIM (51.43%) had been diagnosed with Crohn's disease (CD), and 34 (48.57%) with ulcerative colitis (UC). The CD group included more men (n=21, 58.33%), whereas their proportion in the UC group was 47.02% (n=16). The mean age at CD diagnosis in the UC and CD groups was comparable: 38.3±13.7 years in men with CD and 40.5±12.8 years in men with UC, 37.7±11.1 years in women with CD and 35.7±14.0 in women with UC. The most prevalent among all IBD patients were X-ray negative peripheral arthralgias. Among joint lesions confirmed by radiological diagnostics, sacroileitis was most prevalent both in all IBD patients (24.3%), as well as in the UC group (17.6%), whereas in the CD patients its frequency was the same as that of ankylosing spondyloarthritis (AS) (30.6% of the cases). AS ranked second in the prevalence of joint lesions in the UC group (8.8%) and all IBD (20%). Psoriatic arthritis was diagnosed only in the CD patients (2 / 36). We describe a clinical case of CD with AS, complicated with psoriatic rash, treated with a monoclonal antibody to tumor necrosis factor alfa (anti-TNF-α).Conclusion: Peripheral arthropathias were most prevalent among all joint lesions in the group studied. EIM mirror a more aggressive phenotype of the disease and higher glucocorticosteroids requirements. Administration of anti-TNF-α agents allows for the control of both intestinal IBD manifestations and of the joint syndrome. However, drug-associated skin adverse event can occur during treatment with this drug class. In such a case, it is possible to switch the biological therapy to another class of drugs that we have demonstrated with the given clinical example.

show abstract

Cutaneous manifestations in inflammatory bowel disease (Review)

Cited by 15 publications

References 54 publications

The Temporal Relationships and Associations between Cutaneous Manifestations and Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study

The Temporal Relationships and Associations between Cutaneous Manifestations and Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study

Mucocutaneous Manifestations of Inflammatory Bowel Disease

Joint lesions in inflammatory bowel diseases: the analysis of the Moscow regional patient registry and a clinical case

Contact Info

Product

Resources

About